Zacks Research Issues Positive Estimate for Integer Earnings

Integer Holdings Co. (NYSE:ITGR) – Zacks Research increased their Q2 2025 earnings per share estimates for shares of Integer in a research report issued on Thursday, March 13th. Zacks Research analyst D. Dey now forecasts that the medical equipment provider will post earnings per share of $1.44 for the quarter, up from their previous estimate of $1.43. The consensus estimate for Integer’s current full-year earnings is $6.01 per share. Zacks Research also issued estimates for Integer’s Q3 2025 earnings at $1.57 EPS, FY2025 earnings at $5.98 EPS, Q1 2026 earnings at $1.59 EPS, Q2 2026 earnings at $1.54 EPS, FY2026 earnings at $6.58 EPS and FY2027 earnings at $7.15 EPS.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). The company had revenue of $449.50 million for the quarter, compared to the consensus estimate of $446.28 million. Integer had a return on equity of 11.65% and a net margin of 6.92%.

ITGR has been the topic of a number of other research reports. Oppenheimer downgraded Integer from an “outperform” rating to a “market perform” rating in a research note on Friday, February 21st. Citigroup upped their price objective on Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, December 11th. Truist Financial upped their price objective on Integer from $147.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. KeyCorp increased their target price on Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Finally, Benchmark increased their target price on Integer from $140.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $149.00.

Integer Stock Performance

Shares of ITGR opened at $118.87 on Monday. Integer has a 52 week low of $107.11 and a 52 week high of $146.36. The stock has a 50 day moving average price of $133.56 and a two-hundred day moving average price of $132.61. The firm has a market capitalization of $4.00 billion, a P/E ratio of 35.38, a P/E/G ratio of 1.72 and a beta of 1.24. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.09 and a current ratio of 2.95.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Mather Group LLC. increased its stake in Integer by 304.3% in the fourth quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 143 shares during the last quarter. Lee Danner & Bass Inc. purchased a new stake in Integer during the fourth quarter valued at about $27,000. Huntington National Bank boosted its position in Integer by 8,933.3% during the third quarter. Huntington National Bank now owns 271 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 268 shares during the period. R Squared Ltd purchased a new stake in Integer during the fourth quarter valued at about $44,000. Finally, Sterling Capital Management LLC boosted its position in Integer by 472.9% during the fourth quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 279 shares during the period. Institutional investors own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.